Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

Launched by UNIVERSITY OF NEBRASKA · Aug 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of combining two treatments for people who have been poisoned by carbon monoxide (CO). Carbon monoxide poisoning can lead to serious long-term brain problems for some patients. The researchers want to see if adding a steroid called dexamethasone to the standard treatment of hyperbaric oxygen therapy (HBO) can improve recovery and reduce the risk of long-term neurological issues. Hyperbaric oxygen therapy involves breathing pure oxygen in a special chamber, which helps the body heal from the effects of CO exposure.

To participate in this trial, individuals must be 18 years or older and have experienced acute CO poisoning, either by accident or intentionally, and be receiving HBO treatment at Nebraska Medicine. Some people, like those on mechanical ventilation or with allergies to dexamethasone, may not be eligible to join. Those who do participate can expect to receive the standard HBO treatment along with the steroid and will be monitored to see how well they recover. This trial is still in the planning stages and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute CO poisoning, intentional or non-intentional exposure, receiving HBO treatment during hospitalization
• • Age \>18 years
• • Nebraska Medicine admission
• Exclusion Criteria:
• • Mechanical ventilation
• • No hospital admission or admission to hospital Critical Care Medicine Service
• • Allergy to dexamethasone
• • Pre-Existing neurological condition confounding outcome determination